Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,351–1,360 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1351
- Medicine slug
- rivaroxaban
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 26
- Source count
- 26
- Agreement rate
- 0.923077
- Recorded readings
5 to 9 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 24
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 24 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8e4275c-6cbe-4976-8cae-f62baf954d27 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57717a31-d9d3-4246-90c0-4e4c0a29adf5 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65727928-9421-4df8-bff2-f72a9cc78069 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5524f30f-789d-4f5c-8f7c-d03a475b6d34 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e9ab975-db2f-423c-a089-bc5a73313609 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45f16f1b-e405-4aa6-bc8b-977d4864af3e (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e76bf2cf-a8b8-4471-a8ce-57c918b11a48 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:481b7802-5093-43e7-bbd9-1532197eb6e6 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e95389b-0a93-4560-98c5-02637fb2600f (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:702fed3e-ae25-49ba-98cc-562e0e244214 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:122e6f78-067b-9065-adb2-ec7fec9f008e (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0e105f6-28f3-45ee-83bd-7d458835242b (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9178947d-9d58-4c1a-b158-6030e17556af (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:291011aa-60eb-4109-b59c-1c521fbeac4f (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0ef9361-f06d-4028-97af-183b545f4aea (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38b11f5d-f0fc-46dc-aef1-ea31872bb621 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fee7136-c8fd-4bea-ab15-7a0e7292396d (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcb0e6e7-3006-4d82-8009-c5fddbbfc80d (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0efa9f9-ca7a-471a-8030-99056fa5da09 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10db92f9-2300-4a80-836b-673e1ae91610 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e98f6d83-5172-97a1-ee41-5d7d1d8ba2fd (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e62f23c6-89f2-4179-95dc-5732401b3f93 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:925a9a11-ae5b-405c-96d2-b1be4b85bf71 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88246a0e-befe-4dc6-81e1-4b7adc266db2 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2f55475-2a98-43f3-9eac-93995904ebc5 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 hours to 9 hours in healthy subjects aged 20 years to 45 years.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b53cebf-946c-b82b-e063-6394a90a5da7 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The terminal elimination half-life of rivaroxaban is 5 hours to 9 hours in healthy subjects aged 20 years to 45 years.
Projected row 1352
- Medicine slug
- rivaroxaban
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 26
- Source count
- 26
- Agreement rate
- 1
- Recorded readings
92%
- Numeric value
- 92
- Unit
- %
- Source records
- 26
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 26 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8e4275c-6cbe-4976-8cae-f62baf954d27 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57717a31-d9d3-4246-90c0-4e4c0a29adf5 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65727928-9421-4df8-bff2-f72a9cc78069 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5524f30f-789d-4f5c-8f7c-d03a475b6d34 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e9ab975-db2f-423c-a089-bc5a73313609 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45f16f1b-e405-4aa6-bc8b-977d4864af3e (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2f55475-2a98-43f3-9eac-93995904ebc5 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e76bf2cf-a8b8-4471-a8ce-57c918b11a48 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:481b7802-5093-43e7-bbd9-1532197eb6e6 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e95389b-0a93-4560-98c5-02637fb2600f (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:702fed3e-ae25-49ba-98cc-562e0e244214 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92 % to 95 %, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:122e6f78-067b-9065-adb2-ec7fec9f008e (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0e105f6-28f3-45ee-83bd-7d458835242b (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9178947d-9d58-4c1a-b158-6030e17556af (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:291011aa-60eb-4109-b59c-1c521fbeac4f (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b53cebf-946c-b82b-e063-6394a90a5da7 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0ef9361-f06d-4028-97af-183b545f4aea (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38b11f5d-f0fc-46dc-aef1-ea31872bb621 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fee7136-c8fd-4bea-ab15-7a0e7292396d (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcb0e6e7-3006-4d82-8009-c5fddbbfc80d (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0efa9f9-ca7a-471a-8030-99056fa5da09 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10db92f9-2300-4a80-836b-673e1ae91610 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e98f6d83-5172-97a1-ee41-5d7d1d8ba2fd (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e62f23c6-89f2-4179-95dc-5732401b3f93 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:925a9a11-ae5b-405c-96d2-b1be4b85bf71 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88246a0e-befe-4dc6-81e1-4b7adc266db2 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.
Projected row 1353
- Medicine slug
- rivaroxaban
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 26
- Source count
- 26
- Agreement rate
- 1
- Recorded readings
50 L
- Numeric value
- 50
- Unit
- L
- Source records
- 26
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 26 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8e4275c-6cbe-4976-8cae-f62baf954d27 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57717a31-d9d3-4246-90c0-4e4c0a29adf5 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65727928-9421-4df8-bff2-f72a9cc78069 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5524f30f-789d-4f5c-8f7c-d03a475b6d34 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e9ab975-db2f-423c-a089-bc5a73313609 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45f16f1b-e405-4aa6-bc8b-977d4864af3e (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2f55475-2a98-43f3-9eac-93995904ebc5 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e76bf2cf-a8b8-4471-a8ce-57c918b11a48 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:481b7802-5093-43e7-bbd9-1532197eb6e6 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e95389b-0a93-4560-98c5-02637fb2600f (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:702fed3e-ae25-49ba-98cc-562e0e244214 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:122e6f78-067b-9065-adb2-ec7fec9f008e (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0e105f6-28f3-45ee-83bd-7d458835242b (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9178947d-9d58-4c1a-b158-6030e17556af (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:291011aa-60eb-4109-b59c-1c521fbeac4f (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b53cebf-946c-b82b-e063-6394a90a5da7 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0ef9361-f06d-4028-97af-183b545f4aea (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38b11f5d-f0fc-46dc-aef1-ea31872bb621 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fee7136-c8fd-4bea-ab15-7a0e7292396d (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcb0e6e7-3006-4d82-8009-c5fddbbfc80d (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0efa9f9-ca7a-471a-8030-99056fa5da09 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10db92f9-2300-4a80-836b-673e1ae91610 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e98f6d83-5172-97a1-ee41-5d7d1d8ba2fd (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e62f23c6-89f2-4179-95dc-5732401b3f93 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:925a9a11-ae5b-405c-96d2-b1be4b85bf71 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88246a0e-befe-4dc6-81e1-4b7adc266db2 (opens source in a new tab)
Rivaroxaban label
Version not recorded · Effective date not recorded
The steady-state volume of distribution in healthy subjects is approximately 50 L.
Projected row 1354
- Medicine slug
- rivastigmine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
36%
- Numeric value
- 36
- Unit
- %
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4364f6ef-a8da-4805-be0d-aabbe8ca2d21 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Absolute bioavailability after a 3-mg dose is about 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bb5e0d6-f677-4021-9888-3ff90979ef7d (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Absolute bioavailability after a 3-mg dose is about 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bac9ca81-db70-41aa-82af-6c5bb8496846 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Absolute bioavailability after a 3 mg dose is about 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0044f1d7-613c-4611-8481-13032c8cb390 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Absolute bioavailability after a 3-mg dose is about 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83bd2ff6-1d8b-4cac-a37b-fd01dc3f34a1 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Absolute bioavailability after a 3 mg dose is about 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c246a0e5-1e77-41ee-a7b3-384f21f2f2e0 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Absolute bioavailability after a 3 mg dose is about 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7e641fe-39bd-4681-a430-6dedeb6d6af5 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Absolute bioavailability after a 3-mg dose is about 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:209f3b02-0acf-46e9-b355-91c918a20eb3 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Absolute bioavailability after a 3-mg dose is about 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33e6a772-382d-45f5-9d45-966c07759367 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Absolute bioavailability after a 3-mg dose is about 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e20124c-725a-0145-996c-2ff908703162 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Absolute bioavailability after a 3 mg dose is about 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39aadc39-0f4f-44f7-88de-83a0ea2ac332 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Absolute bioavailability after a 3 mg dose is about 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52781229-ee82-43f9-a113-4419a611978d (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Absolute bioavailability after a 3 mg dose is about 36%.
Projected row 1355
- Medicine slug
- rivastigmine
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 0.571429
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 16
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 16 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after patch removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c569f760-f311-42ba-909c-a36319622b35 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after patch removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6ed6d15-116d-4596-92ce-3414574d7ba0 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after patch removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92a58ebb-748d-49f4-bf11-ecbcf5424152 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after patch removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ab335d1-19ee-4cd9-9776-8086645d19e4 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after transdermal system removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b671fc9-8cb0-4406-a9ee-7c95086d6200 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after patch removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b809739-8381-4cc1-ab4a-5b17ab902a3d (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after transdermal system removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7f9328e-b6da-4474-ac93-3cdd4825e163 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after patch removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cd5c434-ffd0-4aed-9eba-145c86b115bb (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after patch removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ebeb8ec-5348-4bb1-ab3d-834690351094 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after patch removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64dad603-2389-456b-8c18-d1d40b7e7419 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after transdermal system removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a68d70c9-19f2-47db-bf78-4da04a87a702 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after patch removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b201fe68-b5e5-4a6f-8cf1-069543f03e76 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after patch removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82630f84-fb47-47ab-8ee2-1720a486de02 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after patch removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6cc286d9-c5d4-4505-83bb-9015e3077851 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after patch removal.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d8823c0-9339-4ec8-8a19-d13974b6614b (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The apparent elimination half-life in plasma is approximately 3 hours after patch removal.
1.5 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4364f6ef-a8da-4805-be0d-aabbe8ca2d21 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The elimination half-life is about 1.5 hours, with most elimination as metabolites via the urine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bb5e0d6-f677-4021-9888-3ff90979ef7d (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The elimination half-life is about 1.5 hours, with most elimination as metabolites via the urine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bac9ca81-db70-41aa-82af-6c5bb8496846 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The elimination half-life is about 1.5 hours, with most elimination as metabolites via the urine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0044f1d7-613c-4611-8481-13032c8cb390 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The elimination half-life is about 1.5 hours, with most elimination as metabolites via the urine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83bd2ff6-1d8b-4cac-a37b-fd01dc3f34a1 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The elimination half-life is about 1.5 hours, with most elimination as metabolites via the urine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c246a0e5-1e77-41ee-a7b3-384f21f2f2e0 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The elimination half-life is about 1.5 hours, with most elimination as metabolites via the urine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7e641fe-39bd-4681-a430-6dedeb6d6af5 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The elimination half-life is about 1.5 hours, with most elimination as metabolites via the urine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:209f3b02-0acf-46e9-b355-91c918a20eb3 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The elimination half-life is about 1.5 hours, with most elimination as metabolites via the urine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33e6a772-382d-45f5-9d45-966c07759367 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The elimination half-life is about 1.5 hours, with most elimination as metabolites via the urine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e20124c-725a-0145-996c-2ff908703162 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The elimination half-life is about 1.5 hours, with most elimination as metabolites via the urine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39aadc39-0f4f-44f7-88de-83a0ea2ac332 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The elimination half-life is about 1.5 hours, with most elimination as metabolites via the urine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52781229-ee82-43f9-a113-4419a611978d (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
The elimination half-life is about 1.5 hours, with most elimination as metabolites via the urine.
Projected row 1356
- Medicine slug
- rivastigmine
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
40%
- Numeric value
- 40
- Unit
- %
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4364f6ef-a8da-4805-be0d-aabbe8ca2d21 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c569f760-f311-42ba-909c-a36319622b35 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6ed6d15-116d-4596-92ce-3414574d7ba0 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92a58ebb-748d-49f4-bf11-ecbcf5424152 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bb5e0d6-f677-4021-9888-3ff90979ef7d (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ab335d1-19ee-4cd9-9776-8086645d19e4 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Figure 2: Rivastigmine Plasma Concentrations Following Dermal 24-Hour Transdermal System Application Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b671fc9-8cb0-4406-a9ee-7c95086d6200 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b809739-8381-4cc1-ab4a-5b17ab902a3d (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bac9ca81-db70-41aa-82af-6c5bb8496846 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7f9328e-b6da-4474-ac93-3cdd4825e163 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cd5c434-ffd0-4aed-9eba-145c86b115bb (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0044f1d7-613c-4611-8481-13032c8cb390 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83bd2ff6-1d8b-4cac-a37b-fd01dc3f34a1 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c246a0e5-1e77-41ee-a7b3-384f21f2f2e0 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ebeb8ec-5348-4bb1-ab3d-834690351094 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7e641fe-39bd-4681-a430-6dedeb6d6af5 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64dad603-2389-456b-8c18-d1d40b7e7419 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:209f3b02-0acf-46e9-b355-91c918a20eb3 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33e6a772-382d-45f5-9d45-966c07759367 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e20124c-725a-0145-996c-2ff908703162 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a68d70c9-19f2-47db-bf78-4da04a87a702 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b201fe68-b5e5-4a6f-8cf1-069543f03e76 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Figure 2 Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82630f84-fb47-47ab-8ee2-1720a486de02 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39aadc39-0f4f-44f7-88de-83a0ea2ac332 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6cc286d9-c5d4-4505-83bb-9015e3077851 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d8823c0-9339-4ec8-8a19-d13974b6614b (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52781229-ee82-43f9-a113-4419a611978d (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Distribution Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.
Projected row 1357
- Medicine slug
- rivastigmine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4364f6ef-a8da-4805-be0d-aabbe8ca2d21 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Peak plasma concentrations are reached in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bb5e0d6-f677-4021-9888-3ff90979ef7d (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Peak plasma concentrations are reached in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bac9ca81-db70-41aa-82af-6c5bb8496846 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Peak plasma concentrations are reached in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0044f1d7-613c-4611-8481-13032c8cb390 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Peak plasma concentrations are reached in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83bd2ff6-1d8b-4cac-a37b-fd01dc3f34a1 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Peak plasma concentrations are reached in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c246a0e5-1e77-41ee-a7b3-384f21f2f2e0 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Peak plasma concentrations are reached in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7e641fe-39bd-4681-a430-6dedeb6d6af5 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Peak plasma concentrations are reached in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:209f3b02-0acf-46e9-b355-91c918a20eb3 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Peak plasma concentrations are reached in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33e6a772-382d-45f5-9d45-966c07759367 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Peak plasma concentrations are reached in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e20124c-725a-0145-996c-2ff908703162 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Peak plasma concentrations are reached in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39aadc39-0f4f-44f7-88de-83a0ea2ac332 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Peak plasma concentrations are reached in approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52781229-ee82-43f9-a113-4419a611978d (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
Peak plasma concentrations are reached in approximately 1 hour.
Projected row 1358
- Medicine slug
- rivastigmine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
1.8 to 2.7 L/kg
- Numeric value
- 1.8
- Unit
- L/kg
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4364f6ef-a8da-4805-be0d-aabbe8ca2d21 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c569f760-f311-42ba-909c-a36319622b35 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6ed6d15-116d-4596-92ce-3414574d7ba0 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92a58ebb-748d-49f4-bf11-ecbcf5424152 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bb5e0d6-f677-4021-9888-3ff90979ef7d (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ab335d1-19ee-4cd9-9776-8086645d19e4 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b671fc9-8cb0-4406-a9ee-7c95086d6200 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b809739-8381-4cc1-ab4a-5b17ab902a3d (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bac9ca81-db70-41aa-82af-6c5bb8496846 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution (V D ) in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7f9328e-b6da-4474-ac93-3cdd4825e163 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cd5c434-ffd0-4aed-9eba-145c86b115bb (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0044f1d7-613c-4611-8481-13032c8cb390 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution (V D ) in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83bd2ff6-1d8b-4cac-a37b-fd01dc3f34a1 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c246a0e5-1e77-41ee-a7b3-384f21f2f2e0 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution (V D ) in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ebeb8ec-5348-4bb1-ab3d-834690351094 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7e641fe-39bd-4681-a430-6dedeb6d6af5 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution (V D ) in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64dad603-2389-456b-8c18-d1d40b7e7419 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:209f3b02-0acf-46e9-b355-91c918a20eb3 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution (V D ) in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33e6a772-382d-45f5-9d45-966c07759367 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e20124c-725a-0145-996c-2ff908703162 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution (V D ) in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a68d70c9-19f2-47db-bf78-4da04a87a702 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b201fe68-b5e5-4a6f-8cf1-069543f03e76 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82630f84-fb47-47ab-8ee2-1720a486de02 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39aadc39-0f4f-44f7-88de-83a0ea2ac332 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution (V D ) in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6cc286d9-c5d4-4505-83bb-9015e3077851 (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d8823c0-9339-4ec8-8a19-d13974b6614b (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution in the range of 1.8 to 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52781229-ee82-43f9-a113-4419a611978d (opens source in a new tab)
Rivastigmine label
Version not recorded · Effective date not recorded
It has an apparent volume of distribution (V D ) in the range of 1.8 to 2.7 L/kg.
Projected row 1359
- Medicine slug
- rizatriptan
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
45%
- Numeric value
- 45
- Unit
- %
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27bc2cfc-fefb-4b50-a0dc-6268c69b4902 (opens source in a new tab)
Rizatriptan label
Version not recorded · Effective date not recorded
The mean oral absolute bioavailability of the rizatriptan benzoate tablet is about 45%, and mean peak plasma concentrations (C max ) are reached in approximately 1 to 1.5 hours (T max ).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7db81532-6781-47f7-a5cd-6aeda9b8bf6f (opens source in a new tab)
Rizatriptan label
Version not recorded · Effective date not recorded
The mean oral absolute bioavailability of the rizatriptan benzoate tablet is about 45%, and mean peak plasma concentrations (C max ) are reached in approximately 1 to 1.5 hours (T max ).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f000d96c-42a0-4aac-96ca-8cef289979ce (opens source in a new tab)
Rizatriptan label
Version not recorded · Effective date not recorded
The mean oral absolute bioavailability of the rizatriptan benzoate tablet is about 45%, and mean peak plasma concentrations (C max ) are reached in approximately 1 to 1.5 hours (T max ).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34395ed2-97b7-4220-9089-0e90169d3083 (opens source in a new tab)
Rizatriptan label
Version not recorded · Effective date not recorded
The mean oral absolute bioavailability of the rizatriptan benzoate tablet is about 45%, and mean peak plasma concentrations (C max ) are reached in approximately 1 to 1.5 hours (T max ).
Projected row 1360
- Medicine slug
- rizatriptan
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
2 to 3 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27bc2cfc-fefb-4b50-a0dc-6268c69b4902 (opens source in a new tab)
Rizatriptan label
Version not recorded · Effective date not recorded
The plasma half-life of rizatriptan in males and females averages 2 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7db81532-6781-47f7-a5cd-6aeda9b8bf6f (opens source in a new tab)
Rizatriptan label
Version not recorded · Effective date not recorded
The plasma half-life of rizatriptan in males and females averages 2 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f000d96c-42a0-4aac-96ca-8cef289979ce (opens source in a new tab)
Rizatriptan label
Version not recorded · Effective date not recorded
The plasma half-life of rizatriptan in males and females averages 2 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34395ed2-97b7-4220-9089-0e90169d3083 (opens source in a new tab)
Rizatriptan label
Version not recorded · Effective date not recorded
The plasma half-life of rizatriptan in males and females averages 2 to 3 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1350Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.